-
CBIS Portfolio Company:Gilead Sciences
-
Date:06/30/2017
-
CRI Update:
CBIS began its engagement with Gilead Sciences on the issue of access to health for the world’s poor in 2016. CBIS has already met with the access to Medicine Foundation to discuss ways Gilead and the pharmaceutical industry can help the world’s poorest people access the medicine they need. Pharmaceutical companies have an important role to play by responding with concrete, effective action to combat diseases that disproportionately affect the poor and vulnerable. Expanding the supply of life-saving medications can help meet an urgent public health need in low-income countries. Gilead produces and has improved access to medications in developing countries for HIV, hepatitis, and disease caused by parasites. CBIS will work with Gilead to ensure the company is evaluating reduced pricing options to expand coverage for patients, coordinating and supporting education for medical and clinical workers, and expanding innovative patent agreements to hepatitis therapies.
In the first quarter of 2017, CBIS and other shareholders had a call in April to discuss Gilead’s new focus:
- Market expansion: To tackle the Hepatitis C crisis, Gilead will build new manufacturing plants in China where 10 million people are infected. Gilead hopes to replace outdated medications with poor cure rates.
- Pilot projects: Gilead donated drugs to the government of Georgia, the country with the world’s third highest prevalence of hepatitis C. The goal is a 90% reduction in prevalence by 2020.
- Global frameworks: The company committed to meet the UN Sustainable Development Goal of ensuring healthy lives and well-being worldwide by 2030, a positive step.
- Catholic Responsible Investments
Reports
Market Perspectives
Timely and thought-provoking insights from the CBIS Investment Team, key considerations for Catholic Responsible Investing (CRI) investors, and active ownership updates from the Impact & Justice team.
CRI Quarterly Review Q2 2024
CRI Quarterly Review Q1 2024
CRI Quarterly Review – Q4 2023
CRI Quarterly Review – Q3 2023
CRI Quaterly Review – 2Q 2023
CRI Quaterly Review – 1Q 2023
CRI Quarterly Review – 4Q 2022
CRI Quarterly Review – 3Q 2022
Market Overview Q2 2022
CRI Quarterly Review – 2Q 2022
CRI Quarterly Review – 1Q 2022
CRI Quarterly Review – 4Q 2021
Quarterly Review – 3Q 2021
2Q2021 Market Perspective: The Haves and the Have-Nots
1Q2021 Market Perspective: How the Economic Recovery Impacts Markets, Inflation and Productivity
4Q2020 Market Perspective: 2021: The Case for Conviction
3Q2020 Market Overview: Monetary and Fiscal Stimulus
2Q2020 Market Overview: It’s Daybreak, the Sails are Set, but the Seas Remain Turbulent
1Q2020 Market Overview: Navigating through a pandemic that stopped the world
4Q2019 Market Overview: Stage is Set for Continued Economic Growth in 2020
3Q 2019 Market Overview: Value & Growth Strategies Since the Global Financial Crisis
Q2 2019 Market Overview: Tariffs Taking Their Toll
Q1 2019 Market Overview: Markets Roar Back
Q4 2018 Market Overview: Optimism After a Year
Q3 2018 Market Overview: A Look Back – The 2008 Global Financial Crisis
Q2 2018 Market Overview: The Trade Deficit and Tariffs
Q1 2018 Market Overview: The Return of Volatility
Q4 2017 Market Overview: Another Strong Year
Q3 2017 Market Overview: Aging Bull
Q2 2017 Market Overview: Still Great Expectations
Q1 2017 Market Overview: Be Prepared
Q4 2016 Market Overview: A Very Political Economy
Q3 2016 Market Overview: The Yogi Berra Market
Q2 2016 Market Overview: The Value Malaise
CRI Issue Reports
- 2024 Impact Report Download PDF
- Inaugural Impact Report Download PDF
- Divestment: Targeted Fossil Fuels Download PDF
- CBIS Encouraged by BP Commitment to Tackle Fossil Fuel Emissions Download PDF
- Human Trafficking – The Supply Chain Challenge Download PDF
- Supply Chain Accountability Download PDF
- Corporate Strategies to Address Human Trafficking Download PDF
- BP & Shell Decisions Download PDF
- Climate Change Download PDF
Impact and Justice Reports
- I&J Quarterly Review – Q2 2024 Download PDF
- I&J Quarterly Review – Q1 2024 Download PDF
- I&J Quarterly Review – Q4 2023 Download PDF
- I&J Quarterly Review – Q3 2023 Download PDF
- I&J Quarterly Review – 2Q 2023 Download PDF
- I&J Quarterly Review – 1Q 2023 Download PDF
- I&J Quarterly Review – 4Q 2022 Download PDF
- I&J Quarterly Review – 3Q 2022 Download PDF
- I&J Quarterly Review – 2Q 2022 Download PDF
- Impact & Justice: July 2021 Download PDF
- Impact & Justice: May 2021 Download PDF
- Impact & Justice: February 2021 Download PDF
- Impact & Justice: October 2020 Download PDF
- Impact & Justice: August 2020 Download PDF
- Impact & Justice Supplement: A Holistic Approach Download PDF
- Impact & Justice: April 2020 – COVID-19 Update Download PDF
- Impact and Justice: January 2020 – Vatican Summit Download PDF
- Impact and Justice: September 2019 Download PDF
CRI Progress Reports
For each of the Impact & Justice engagements, the team establishes short- and long-term goals in order to measure and evaluate progress. Goals are dependent on how far along a company is towards identifying and addressing an issue.
The Catholic Responsible Investing approach centers on three key principles: Economic Justice, Care for Creation, and Human Dignity.